Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

37 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effects of Rolapitant Administered Intravenously or Orally on the Pharmacokinetics of Digoxin (P-glycoprotein Substrate) and Sulfasalazine (Breast Cancer Resistance Protein Substrate) in Healthy Volunteers.
Wang X, Zhang ZY, Arora S, Hughes L, Wang J, Powers D, Christensen J, Lu S, Kansra V. Wang X, et al. Among authors: kansra v. J Clin Pharmacol. 2018 Feb;58(2):202-211. doi: 10.1002/jcph.1005. Epub 2017 Sep 14. J Clin Pharmacol. 2018. PMID: 28906558 Clinical Trial.
Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects.
Wang J, Zhang ZY, Lu S, Powers D, Kansra V, Wang X. Wang J, et al. Among authors: kansra v. Support Care Cancer. 2019 Mar;27(3):819-827. doi: 10.1007/s00520-018-4331-x. Epub 2018 Aug 6. Support Care Cancer. 2019. PMID: 30084103 Free PMC article. Clinical Trial.
37 results